Clinical efficacy of botulinum toxin in lateral elbow tendinopathy: A systematic review and meta-analysis of randomized controlled trials - 23/12/23

Doi : 10.1016/j.otsr.2023.103733

Félix Vilchez-Cavazos ^a, Carlos A. Acosta-Olivo ^a, Luis E. Simental-Mendía ^b, Edgar G. Dorsey-Treviño ^a, Víctor M. Peña-Martínez ^a, Mario Simental-Mendía ^a,⁎
^a Universidad Autonoma de Nuevo Leon, Orthopedic Trauma Service, University Hospital “Dr. José Eleuterio González”, School of Medicine, Monterrey, Mexico
^b Instituto Mexicano del Seguro Social, Unidad de Investigación Biomédica, Delegación Durango, Durango, Mexico

^*Corresponding author. Orthopedic Trauma Service, “Dr. José Eleuterio González” University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Ave. Francisco I. Madero and Ave. Dr. José Eleuterio González, 64460 Monterrey, Nuevo León, Mexico.Orthopedic Trauma Service, “Dr. José Eleuterio González” University Hospital, School of Medicine, Universidad Autónoma de Nuevo LeónAve. Francisco I. Madero and Ave. Dr. José Eleuterio GonzálezMonterrey, Nuevo León64460Mexico

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Saturday 23 December 2023

Highlights

•	Botulinum toxin significantly reduce pain on lateral elbow tendinopathy.
•	Changes in pain relief did not reach clinical significance for botulinum toxin.
•	Botulinum toxin is safe and effective in the short-term.

Le texte complet de cet article est disponible en PDF.

Abstract

Background

Botulinum toxin injections for lateral elbow tendinopathy have been used as an alternative therapeutic option. However, few studies have quantitatively summarized the effect of botulinum toxin as well as its clinical significance. We aimed to evaluate the clinical efficacy (based on pain and grip strength) and adverse events of botulinum toxin on lateral elbow tendinopathy.

Patients and methods

The MEDLINE, EMBASE, Web of Science, and Scopus databases were searched until March 2023 for randomized controlled trials reporting the effects of botulinum toxin injections on lateral elbow tendinopathy. A random- or fixed-effects model (depending of inter-study variability) and generic inverse variance method were used to pool quantitative data from outcomes. The risk of bias was assessed with the Cochrane Risk of Bias 2.0 tool.

Results

A total of 8 clinical trials recruiting 438 subjects were included for meta-analysis. Pooled analysis revealed that botulinum toxin significantly reduced pain (mean difference [MD] −0.95, 95% CI [−1.63, −0.26], p=0.007) but it was not clinically relevant. No significant effect was detected for grip strength (MD–0.62kg, 95% CI [–2.25, 1.02], p=0.46) or in the risk for adverse events (odds ratio [OR] 0.41, 95% CI [0.05, 3.56], p=0.42) between botulinum toxin injection and control interventions.

Discussion

The use of botulinum toxin reached greater pain relief than control interventions and normal saline after a period of 12 to 24 weeks. However, changes in pain relief did not reach clinical significance. The studies that had the greatest reduction in pain used higher doses of botulinum toxin (60 U). Additionally, differences in grip strength and adverse events did not reach statistical or clinical importance. A subanalysis indicated that botulinum toxin outperformed corticosteroid injections in terms of improving grip strength. Botulinum toxin only causes local and minimal side effects such as irritation, ecchymosis, and paralysis.